SEPARATION AGREEMENTSeparation Agreement • March 14th, 2019 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • California
This letter sets forth the substance of the separation agreement (the “Agreement”) that Eiger BioPharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition.
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 14th, 2019 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of April 24, 2017, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (“Parent”), EB Pharma, LLC, a Delaware limited liability company (“EB Pharma”) and EBPI Merger, Inc. (“EBPI”), each with offices located at 350 Cambridge Ave. Suite 350, Palo Alto, CA 94306 (Parent, EB Pharma and EBPI, individually and collectively, jointly and severally, “Borrower”).
